The Myelin Repair Foundation And National Institutes of Health (NIH) Enter Agreement For The Clinical Development Of MRF-008, A Drug Repurposing Opportunity For Multiple Sclerosis
1/27/2014 10:02:06 AM
SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) today announced it has entered a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to assess MRF-008, as a potential therapeutic for multiple sclerosis (MS). This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke (NINDS) at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by